EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Targeting Glycolysis for Treatment of Breast Cancer Resistance: Current Progress and Future Prospects

Zixu Niu, Jing He, Siyuan Wang, Bingjian Xue, Hao Zhang, Ruohan Hou, Zimeng Xu, Jing Sun, Fucheng He, Xinhong Pei

International Journal of Biological Sciences · 24.03.2025 · 21 (6) · 2589-2605

DOI: 10.7150/ijbs.109803 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Biological Sciences, erschienen am 24.03.2025. Verfasst von Zixu Niu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. Hauptthemen laut MEDLINE: Glycolysis, Breast Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 29-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer stands as one of the most prevalent malignant tumors threatening women's health and is a leading cause of cancer-related mortality. Its treatment faces significant challenges, including drug tolerance and disease recurrence. Glycolysis serves not only as a critical metabolic pathway for energy acquisition in breast cancer cells but also essentially promotes tumor proliferation, invasion, metastasis, and the development of resistance to therapy. Recent studies have revealed a close association between glycolytic reprogramming and drug resistance in breast cancer, with high-level glycolysis emerging as a hallmark of malignancy, deeply involved in the initiation and progression of tumors. This review summarizes recent advances in research on key enzymes and signaling pathways regulating glycolysis within the bodies of breast cancer patients. It explores in depth these molecular mechanisms and their complex interaction networks, offering a fresh perspective on overcoming drug resistance in breast cancer. Moreover, it underscores the importance of developing specific inhibitors targeting key enzymes and regulators of glycolysis and suggests that combining such inhibitors with existing anticancer drugs could substantially enhance therapeutic outcomes for breast cancer patients and reduce the occurrence of drug resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlycolysisBreast NeoplasmsDrug Resistance, NeoplasmHumansFemaleAntineoplastic AgentsSignal TransductionAnimals

Stichwörter der Autor:innen

Breast cancerDrug resistanceGlycolysisGlycolytic inhibitorsTargeted therapyTumor metabolism

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
  • Pharmaceutical College, Guangxi Medical University, Nanning, 530021, China.
  • The First Clinical Medical College of Zhengzhou University, Zhengzhou, 450052, China.
  • Department of Medical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.

Zitieren

APA

Niu, Z., He, J., Wang, S., Xue, B., Zhang, H., Hou, R., Xu, Z., Sun, J., He, F., & Pei, X. (2025). Targeting Glycolysis for Treatment of Breast Cancer Resistance: Current Progress and Future Prospects. International Journal of Biological Sciences, 21(6), 2589-2605. https://doi.org/10.7150/ijbs.109803

Vancouver

Niu Z, He J, Wang S, Xue B, Zhang H, Hou R, et al. Targeting Glycolysis for Treatment of Breast Cancer Resistance: Current Progress and Future Prospects. International Journal of Biological Sciences. 2025;21(6):2589-2605. doi:10.7150/ijbs.109803

BibTeX
@article{Niu2025,
  author = {Niu, Zixu and He, Jing and Wang, Siyuan and Xue, Bingjian and Zhang, Hao and Hou, Ruohan and Xu, Zimeng and Sun, Jing and He, Fucheng and Pei, Xinhong},
  title = {Targeting Glycolysis for Treatment of Breast Cancer Resistance: Current Progress and Future Prospects},
  journal = {International Journal of Biological Sciences},
  year = {2025},
  volume = {21},
  number = {6},
  pages = {2589--2605},
  doi = {10.7150/ijbs.109803}
}
Kostenlos starten →